Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6828339 | SYNTHON PHARMS | Amlodipine salt forms and processes for preparing them |
Nov, 2022
(1 year, 5 months ago) |
Market Authorisation Date: 27 September, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
US11458095 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
US11723866 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) |
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina
Dosage: SOLUTION;ORAL